VivoSeq
Oncology

Low Grade Glioma

30

Pipeline Programs↗

10

Active Trials↗

18

Companies Involved↗

Low Grade Glioma is an emerging landscape with 30 programs across 18 companies. The most active players are Institut de Recherches Internationales Servier, Day One Biopharmaceuticals, Bristol-Myers Squibb. 7 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

6/100

Mech. Concentration

24/100

Completion Rate

70/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

2 programs

Phase 1Day One Biopharmaceuticals logo

Day One Biopharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2C

Celldex Therapeutics

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

28 of 31 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 97% of 34 pipeline programs.

Analysis

Trial Status

24

clinical trials

Completed7 · 29%
Active, not recruiting5 · 21%
Recruiting5 · 21%
Unknown status4 · 17%
Terminated2 · 8%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

24 trials

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Recruiting·UUniversity Hospital, Strasbourg, France·Phase 2·NCT05180825·134 enrolled
A Vaccine Trial for Low Grade Gliomas
Recruiting·—·Phase 2·NCT02358187·25 enrolled
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
Recruiting·—·Phase 1·NCT06381570·57 enrolled
A Pilot Study Evaluating the Toxicity and Clinical Benefit of Mitogen-activated Protein Kinase (MAPK) Pathway Inhibition Combined With Programmed Cell Death-1 Checkpoint Blockade (Anti-PD1) for the Treatment of BRAF-altered Pediatric Gliomas
Recruiting·AAnn & Robert H Lurie Children's Hospital of Chicago·Preclinical·NCT06712875·27 enrolled
A Phase I, Open-label, Single-arm, Multicentre Study to Evaluate the Safety and Pharmacokinetics of Tovorafenib in Japanese Paediatric Participants With BRAF-altered Recurrent or Progressive Low-grade Glioma
Recruiting·Ipsen logoIpsen·Phase 1·NCT07441707·6 enrolled
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT00887146·305 enrolled
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
Active, not recruiting·—·Phase 3·NCT02455245·95 enrolled
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
Active, not recruiting·TThe Hospital for Sick Children·Phase 2·NCT02840409·109 enrolled
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT01089101·217 enrolled
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03871257·165 enrolled
Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
Completed·UUniversity Hospital, Toulouse·N/A·NCT02286531·93 enrolled
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Completed·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 1·NCT03343197·49 enrolled
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01158651·23 enrolled
A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Completed·MMelbourne Health·Phase 1·NCT05577416·14 enrolled
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Completed·WWake Forest University Health Sciences·Phase 2·NCT01188096·23 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)